Pratia Hematologia Sp. z o.o. — Clinical Trial Site

89 Registered trials

46 Currently recruiting

Organisation

Pratia Hematologia Sp. z o.o.

Location

Katowice, Poland

Identifier

ORG-100040044

Address

Ul. Tadeusza Kosciuszki 92, 40-519, Poland

Departments

-
#5704 Pratia Onkologia Katowice
#9008: oncology
2141: PRATIA Onkologia Katowice
2806 : Pratia Onkologia Katowice
5702: Hematologia
Hematologia
Hematology
n/a
NA
PL30001:Oncology
Poradnia Onkologiczna
Pratia Onkologia Katowice
Pratia Hematologia Sp. z o.o.
Pratia Onkologia
Pratia Onkologia Katowice
Site name:Pratia Onkologia Katowice, ul. Kosciuszki 92, 40-519 Katowice

Clinical trials at this site (89)

Search interface

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting

2023-503442-30-00 Multiple Myeloma 5 2022-10-14
A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting

2023-507699-38-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2022-08-30
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-C… Recruiting

2022-502646-27-00 Relapsed or Refractory Diffuse Large B-Cell Lymphoma 10 2022-06-24
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim… Recruiting

2024-510690-16-00 Relapsed/refractory follicular lymphoma 5 2022-01-31
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C… Recruiting

2024-515273-10-00 Relapsed or refractory Multiple Myeloma (r/r MM) 7 2021-10-19
PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES Recruiting

2024-518454-17-00 relapsed/refractory hematologic malignancies 1 2021-01-08
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects wi… Recruiting

2024-514010-12-00 Advanced Malignancies 1 2020-12-03
A Phase 2 Study to Investigate Sonrotoclax combined with Zanubrutinib Versus Zanubrutinib alone in Patients With Previously Untreated Chroni… Ended

2024-513970-23-00 Previously Untreated Chronic Lymphocytic Leukemia 4 2025-02-27
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL Ended

2023-509258-71-00 relapsed or refractory B‑cell non-Hodgkin lymphomas 1 2024-07-24
A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas… Ended

2023-509947-29-00 Anemia in patients with very low, low or intermediate r 4 2024-07-18
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapse… Ended

2023-508426-10-00 Relapsed/Refractory Multiple Myeloma 3 2024-06-03
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
A Phase III multicenter study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients Ended

2023-505160-12-00 Essential Thrombocythaemia 5 2023-12-04
A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha… Ended

2023-504028-24-00 Large B-Cell Lymphoma 5 2023-09-22
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended

2023-503444-13-00 Relapsed/refractory multiple myeloma 5 2023-03-29
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i… Ended

2023-509859-13-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-11-09
A Phase III Open-Label Trial of Acalabrutinib Plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocyti… Ended

2023-505866-27-00 Chronic Lymphocytic Leukemia or Small Lymphocytic Lymph 5 2022-10-28
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin… Ended

2023-503467-41-00 Relapsed or Refractory Multiple Myeloma 5 2022-10-12
A Study to Evaluate Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone o… Ended

2023-507019-36-00 Relapsed or Refractory Multiple Myeloma (R/R MM) 3 2022-07-08
A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended

2023-508897-27-00 Multiple Myeloma 5 2022-04-28
A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended

2024-511599-33-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-12-22
A Study to Evaluate Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Len… Ended

2023-505807-21-00 Relapsed/refractory follicular lymphoma 5 2021-11-16
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended

2023-503441-55-00 Relapsed/Refractory Multiple Myeloma 4 2021-10-14